BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026

Reuters12-08

Dec 8 (Reuters) - Vaxcyte Inc PCVX.O:

VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS
VAXCYTE INC - TOPLINE RESULTS FROM OPUS TRIAL EXPECTED IN Q4 2026

Source text: ID:nGNX2TF0sD

Further company coverage: PCVX.O

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2589358800?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-08 20:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2589358800","market":"us","top_or_hot":-1,"title":"BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Vaxcyte Inc <span>PCVX.O</span>:</p><ul><li><p>VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS</p></li><li><p>VAXCYTE INC - TOPLINE RESULTS FROM OPUS TRIAL EXPECTED IN Q4 2026</p></li></ul><p>Source text: <span>ID:nGNX2TF0sD</span></p><p>Further company coverage: <span>PCVX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-12-08 20:35</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026</title></head><body><p><span>Dec 8 (Reuters)</span><span> - </span>Vaxcyte Inc <span>PCVX.O</span>:</p><ul><li><p>VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTS</p></li><li><p>VAXCYTE INC - TOPLINE RESULTS FROM OPUS TRIAL EXPECTED IN Q4 2026</p></li></ul><p>Source text: <span>ID:nGNX2TF0sD</span></p><p>Further company coverage: <span>PCVX.O</span></p><p> ((Reuters.Briefs@thomsonreuters.com;))</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0053671581.USD","symbol_name":"摩根大通美国小盘成长股 A(dist)","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251208:nTUABSGKG:1","article_id":"2589358800","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2589358800","pubTimestamp":1765197333,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026Dec 8 (Reuters) - Vaxcyte Inc PCVX.O:VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 ","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0053671581.USD":"摩根大通美国小盘成长股 A(dist)","BK4139":"生物科技","IE0009354923.USD":"JANUS HENDERSON US VENTURE \"A2\" (USD) ACC","PCVX":"Vaxcyte, Inc."},"translate_title":"BRIEF-Vaxcyte表示OPUS试验的主要结果预计将于2026年第四季度公布","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PCVX":0.9},"content_text":"BRIEF-Vaxcyte Says Topline Results From OPUS Trial Expected In Q4 2026Dec 8 (Reuters) - Vaxcyte Inc PCVX.O:VAXCYTE DOSES FIRST PARTICIPANTS IN THE OPUS PHASE 3, NONINFERIORITY TRIAL EVALUATING VAX-31 FOR THE PREVENTION OF INVASIVE PNEUMOCOCCAL DISEASE AND PNEUMONIA IN ADULTSVAXCYTE INC - TOPLINE RESULTS FROM OPUS TRIAL EXPECTED IN Q4 2026Source text: ID:nGNX2TF0sDFurther company coverage: PCVX.O ((Reuters.Briefs@thomsonreuters.com;))","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.11","shortVersion":"4.35.11","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2589358800","isCrawlerRequest":true}